| Date Filed | Type | Description |
| 08/09/2023 |
4
| Musso Alan A (CFO) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 432,800 options to buy
@ $4.01, valued at
$1.7M
|
|
| 08/09/2023 |
3
| Musso Alan A (CFO) has filed a Form 3 on Fulcrum Therapeutics, Inc. |
| 07/03/2023 |
3
| Sapir Alex (See Remarks) has filed a Form 3 on Fulcrum Therapeutics, Inc. |
| 06/29/2023 |
4
| GERAGHTY JAMES A (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.16, valued at
$94.8k
|
|
| 06/29/2023 |
4
| Haviland Kate (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.16, valued at
$94.8k
|
|
| 06/29/2023 |
4
| Dorton Katina (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.16, valued at
$94.8k
|
|
| 06/29/2023 |
4
| Banks Sonja (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.16, valued at
$94.8k
|
|
| 06/29/2023 |
4
| Ezekowitz Alan (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.16, valued at
$94.8k
|
|
| 06/29/2023 |
4
| Gould Robert J (Interim President & CEO) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.16, valued at
$94.8k
|
|
| 06/29/2023 |
4
| Collins James J. (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.16, valued at
$94.8k
|
|
| 05/11/2023 |
4
| Tourangeau Greg (Principal Accounting Officer) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Sold 210 shares
@ $3.31, valued at
$695.1 |
|
| 04/28/2023 |
4
| Hayes Melvin H. III (COO) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 115,000 options to buy
@ $2.58, valued at
$296.7k
|
|
| 04/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/24/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Bought 1,923,076 shares
@ $13, valued at
$25M
|
|
| 01/13/2023 |
4
| Gould Robert J (Interim President & CEO) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Sold 6,766 shares
@ $15, valued at
$101.5k
|
|
| 01/06/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Bought 122,334 shares
@ $7.0276, valued at
$859.7k
Bought 58,369 shares
@ $7.7968, valued at
$455.1k
|
|
| 12/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/15/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/09/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/09/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 08/26/2022 |
3
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 3 on Fulcrum Therapeutics, Inc. |
| 08/11/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/11/2022 |
4
| Oltmans Curtis Gale (Chief Legal Officer) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 50,000 options to buy
@ $7.4, valued at
$370k
|
|
| 08/11/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/19/2022 |
4
| Tourangeau Greg (Controller) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 16,540 options to buy
@ $5.39, valued at
$89.2k
|
|
| 06/29/2022 |
4
| Ezekowitz Alan (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 19,000 options to buy
@ $5.22, valued at
$99.2k
Disposed of 500 options to buy
@ $11.82, valued at
$5.9k
|
|
| 06/29/2022 |
4
| Haviland Kate (Director) has filed a Form 4 on Fulcrum Therapeutics, Inc.|
Txns:
| Granted 19,000 options to buy
@ $5.22, valued at
$99.2k
|
|
| 06/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|